Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.

eqs_en 
0 0 15.12.23
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C. http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
 

EQS-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Takeover/Mergers Acquisitions
Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.

15-Dec-2023 / 17:43 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

 
Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
 
Jena, December 15, 2023

Carl Zeiss Meditec AG (ISIN: DE0005313704) announces today that it has entered into a definitive agreement to acquire 100% of the shares in Dutch Ophthalmic Research Center (International) BV, Zuidland, Netherlands (D.O.R.C.), from the investment firm Eurazeo SE, Paris, France (ISIN: FR0000121121). D.O.R.C. is a leading company in the vitreo-retinal surgery segment with close to EUR 200 million in revenue expected in fiscal 2023 and an operating profit in the mid double digit million EUR range. The acquisition will enhance and compliment Carl Zeiss Meditec’s ophthalmic portfolio for addressing a wide variety of eye conditions, including retinal disorders, cataracts, glaucoma and refractive errors.

The acquisition is expected to close in the first half of calendar year 2024 subject to applicable regulatory and antitrust approvals. The transaction is valued at an enterprise value of approximately EUR 985 million. The purchase price will be paid for primarily by available net liquidity of Carl Zeiss Meditec AG. In order to maintain operational flexibility, the company plans to seek a shareholder loan from Carl Zeiss AG in the amount of EUR 400 million as part of the financing, with a duration of three years and market-standard conditions.

The acquisition should achieve a modest positive contribution (by a single digit percentage amount) to the earnings per share of Carl Zeiss Meditec AG in the first full year after closing.
 

Contact for investors and press

Sebastian Frericks

Head of Group Finance Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: [email protected]

 

 

 

 

 

 

 

 

 



End of Inside Information

15-Dec-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1798059

 
End of Announcement EQS News Service

1798059  15-Dec-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1798059&application_name=news&site_id=sharewise

Carl Zeiss Meditec AG Aktie

66,55 €
0,53 %
Die Carl Zeiss Meditec AG Aktie erlebt heute einen kleinen Anstieg von 0,53 %.
Keine klare Meinung bei der Carl Zeiss Meditec AG Aktie: 2 Buy-Einschätzungen stehen 1 Sell-Einschätzungen gegenüber.
Eine deutliche Steigerung um mehr als 50% ist für Carl Zeiss Meditec AG mit einem Kursziel von 122 € gegenüber 66.55 € zu erwarten.
Mehr anzeigen
Like: 0
Teilen
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Rechtlicher Hinweis

Kommentare

Noch kein Mitglied? Jetzt kostenlos registrieren!